/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ImmunityBio Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.22 0.0526(5.26%) IBRX at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 2.08
Highest Today 2.2
Today’s Open 2.085
Prev. Close 2.09
52 Week High 5.12
52 Week Low 1.83
Day’s Range: Low 2.08 High 2.2
52-Week Range: Low 1.83 High 5.12
1 day return -
1 Week return -6.79
1 month return +6.03
3 month return -7.96
6 month return -24.82
1 year return -53.59
3 year return -62.76
5 year return -76.77
10 year return -

Institutional Holdings

Vanguard Group Inc 2.31

BlackRock Inc 1.88

Bank of America Corp 0.93

Armistice Capital, LLC 0.82

Jane Street Group LLC 0.82

State Street Corp 0.81

Vanguard Total Stock Mkt Idx Inv 0.77

Geode Capital Management, LLC 0.61

iShares Russell 2000 ETF 0.58

Vanguard Small Cap Index 0.57

Woodline Partners LP 0.36

Millennium Management LLC 0.34

SPDR® S&P Biotech ETF 0.33

Vanguard Small Cap Growth Index Inv 0.32

AlphaCore Capital LLC 0.31

Morgan Stanley - Brokerage Accounts 0.31

Citigroup Inc 0.26

TANG CAPITAL MANAGEMENT LLC 0.25

Fidelity Small Cap Index 0.24

Vanguard Institutional Extnd Mkt Idx Tr 0.23

Susquehanna International Group, LLP 0.20

Northern Trust Corp 0.20

Charles Schwab Investment Management Inc 0.19

iShares Russell 2000 Growth ETF 0.17

Royal Bank of Canada 0.13

UBS Group AG 0.13

Fidelity Extended Market Index 0.12

Vanguard Russell 2000 ETF 0.12

JPMorgan Chase & Co 0.11

Schwab US Small-Cap ETF™ 0.10

BSC Private Wealth Management, LLC 0.09

State St Russell Sm Cap® Indx SL Cl I 0.09

JPM Thematics Genetic Thrps C2 dist USD 0.08

Vanguard Health Care ETF 0.07

Schwab Small Cap Index 0.06

NT R2000 Index Fund - NL 0.06

iShares Biotechnology ETF 0.06

Fidelity Nasdaq Composite Index 0.06

iShares Nasdaq US Biotech ETF USD Acc 0.05

NT R2000 Index Fund - DC - NL - 3 0.05

Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2058.58 M

PB Ratio 0.0

PE Ratio 0.0

Enterprise Value 2549.86 M

Total Assets 382.93 M

Volume 12408054

Company Financials

Annual Revenue FY23:556000 0.6M, FY22:240000 0.2M, FY21:934000 0.9M, FY20:605000 0.6M, FY19:2202000 2.2M

Annual Profit FY23:null 0.0M, FY22:240000 0.2M, FY21:934000 0.9M, FY20:605000 0.6M, FY19:2202000 2.2M

Annual Net worth FY23:-458019000 -458.0M, FY22:-417320000 -417.3M, FY21:-349848000 -349.8M, FY20:-224187000 -224.2M, FY19:-160158000 -160.2M

Quarterly Revenue Q3/2025:32061000 32.1M, Q2/2025:26425000 26.4M, Q1/2025:16517000 16.5M, Q3/2024:6106000 6.1M, Q2/2024:1047000 1.0M

Quarterly Profit Q3/2025:27933000 27.9M, Q2/2025:26289000 26.3M, Q1/2025:16459000 16.5M, Q3/2024:6106000 6.1M, Q2/2024:1047000 1.0M

Quarterly Net worth Q3/2025:-67253000 -67.3M, Q2/2025:-92555000 -92.6M, Q1/2025:-129646000 -129.6M, Q3/2024:-85729000 -85.7M, Q2/2024:-134564000 -134.6M

Fund house & investment objective

Company Information ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Organisation Biotechnology

Employees 673

Industry Biotechnology

CEO Mr. Richard Gerald Adcock

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow